8 terminated. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Terminated 8 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes Rifaximin, Placebo - Liver Cirrhosis, Coagulation Disorder | Phase 4 | Terminated | University of Roma La Sapienza | 20 | 2021-04-03 | 2024-10-08 |
| Factor In the Initial Resuscitation of Severe Trauma 2 Patients Fibrinogen + PCC, Frozen Plasma - Traumatic Hemorrhage, Coagulopathy | Phase 4 | Terminated | University Health Network, Toronto | 142 | 2021-04-01 | 2026-10-21 |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Terminated | Takeda | 141 | 2017-11-13 | 2026-05-04 |
| Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Enoxaparin - Anticoagulants and Bleeding Disorders, Surgery | Phase 4 | Terminated | Wake Forest University Health Sciences | 122 | 2017-10-24 | 2023-10-05 |
| Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Bortezomib, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Terminated | Basque Health Service | 24 | 2014-01-01 | 2020-01-18 |
| Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol Group ROTEM, Group C - Hemostatic Disorders | Phase 4 | Terminated | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 49 | 2010-02-01 | 2013-08-09 |
| Study Evaluating The Safety Of Xyntha In Usual Care Settings Moroctocog alfa(AF-CC), Blood draw for laboratory testing - Hemophilia A | Phase 4 | Terminated | Pfizer | 12 | 2009-02-01 | 2012-01-20 |
| Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients Alphanate SD/HT - Von Willebrand Disease | Phase 4 | Terminated | Grifols Biologicals, LLC | 4 | 2008-07-08 | 2026-09-30 |
Hemophilia A (2) · Multiple Myeloma (2) · Blood Platelet Disorders (1) · Endotoxemia (1) · Hematologic Diseases (1) · Hemophilia B (1) · Liver Cirrhosis (1) · Thromboembolism (1) · Thrombosis (1) · Wounds and Injuries (1) · von Willebrand Diseases (1)
Cardiovascular Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Vascular Diseases (8) · Hematologic Diseases (7) · Blood Coagulation Disorders (3) · Blood Coagulation Disorders, Inherited (3) · Coagulation Protein Disorders (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Blood Protein Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2)
Blood Specimen Collection (1) · Bortezomib (1) · Dexamethasone (1) · Enoxaparin (1) · F8 protein, human (1) · Fibrinogen (1) · Lenalidomide (1) · Melphalan (1) · Prednisone (1) · Rifaximin (1) · ixazomib (1) · prothrombin complex concentrates (1)
Basque Health Service (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Grifols Biologicals, LLC (1) · Pfizer (1) · Takeda (1) · University Health Network, Toronto (1) · University of Roma La Sapienza (1) · Wake Forest University Health Sciences (1)
United States (3) · Canada (1) · Italy (1) · New Zealand (1) · Spain (1)
Daryl S Henshaw, MD (1) · Lucia Stefanini, Prof. (1) · Luis T Da Luz, MD (1) · Manuela Merli, Prof. (1) · Oliviero Riggio, Prof. (1) · Pilar Paniagua, MD (1) · Roberto Carnevale, Prof. (1) · Sandra Camprubi (1)
PMID 28492441, PMID 34479938, PMID 37280083, PMID 37807952, PMID 40982282